Document Detail


Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?
MedLine Citation:
PMID:  22088886     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Prior studies have shown an increased vulnerability among males to adverse outcomes during the postnatal period. Most children exposed to opioids and other medications in utero develop neonatal abstinence syndrome (NAS), yet individual predisposition for NAS is poorly understood.
OBJECTIVE: This investigation examined the role of neonatal sex in the postnatal period for neonates exposed to standardized opioid maintenance treatment in utero with a focus on NAS regarding severity, medication requirements, and duration.
METHODS: This was a secondary analysis of data collected in a prospective randomized, double-blind, double-dummy, multicenter trial (MOTHER study) that examined the comparative safety and efficacy of methadone and buprenorphine during pregnancy. A total of 131 neonates born to opioid-dependent women randomized at 6 US sites (n = 74) and 1 European site (n = 37) were analyzed. Sex-based differences in birth weight, length, head circumference, NAS duration, NAS severity, and treatment parameters of full-term neonates were assessed.
RESULTS: Males had a significantly higher birth weight (P = 0.027) and head circumference (P = 0.017) compared with females, with no significant sex difference in rates of preterm delivery. No significant sex-related differences were found for NAS development, severity, or duration, or medication administered, and there were no significant differences in concomitant drug consumption during pregnancy (P = 0.959).
CONCLUSIONS: This unique prospective study shows similar postnatal vulnerability for both sexes, suggesting that factors other than sex are the major determinants of clinically significant NAS. ClinicalTrials.gov identifier: NCT 00271219.
Authors:
Annemarie Unger; Reinhold Jagsch; Andjela Bäwert; Bernadette Winklbaur; Klaudia Rohrmeister; Peter R Martin; Mara Coyle; Gabriele Fischer
Related Documents :
1558656 - Testimony presented at public hearing on regulation of tissue and organ transplantation.
9230536 - A critical appraisal of current management practices for infant regurgitation.
11854816 - Phenobarbital in sera of epileptic mothers and their infants.
8546886 - Aluminum content of infant formulas used in turkey.
1907386 - Indication and results of thoracic surgical procedures in premature infants.
10048606 - Neurodevelopmental outcome at 1 year in zimbabwean neonates with extreme hyperbilirubin...
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural     Date:  2011-11-15
Journal Detail:
Title:  Gender medicine     Volume:  8     ISSN:  1878-7398     ISO Abbreviation:  Gend Med     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-13     Completed Date:  2012-04-19     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  101225178     Medline TA:  Gend Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  355-64     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier HS Journals, Inc. All rights reserved.
Affiliation:
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria. annemarie.unger@meduniwien.ac.at
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00271219
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Birth Weight / drug effects*
Buprenorphine / adverse effects*
Double-Blind Method
Female
Humans
Infant, Newborn
Male
Methadone / adverse effects*
Neonatal Abstinence Syndrome / epidemiology*
Opioid-Related Disorders / epidemiology*
Pregnancy
Pregnancy Complications / chemically induced
Pregnancy Outcome
Prenatal Exposure Delayed Effects / epidemiology*
Prospective Studies
Risk Factors
Severity of Illness Index
Sex Distribution
Sex Factors
Grant Support
ID/Acronym/Agency:
M01RR00095/RR/NCRR NIH HHS; R01 DA018417-01/DA/NIDA NIH HHS; R01 DA018417-02/DA/NIDA NIH HHS; R01 DA018417-03/DA/NIDA NIH HHS; R01 DA018417-04/DA/NIDA NIH HHS; R01 DA018417-04S1/DA/NIDA NIH HHS; R01 DA018417-05/DA/NIDA NIH HHS; R01DA015738/DA/NIDA NIH HHS; R01DA015741/DA/NIDA NIH HHS; R01DA015764/DA/NIDA NIH HHS; R01DA015778/DA/NIDA NIH HHS; R01DA017513/DA/NIDA NIH HHS; R01DA018410/DA/NIDA NIH HHS; R01DA018417/DA/NIDA NIH HHS; R01DA15832/DA/NIDA NIH HHS
Chemical
Reg. No./Substance:
52485-79-7/Buprenorphine; 76-99-3/Methadone
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A reevaluation of the epimeric and anomeric relationship of glucosides and galactosides in thermotro...
Next Document:  Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative...